ArticleClinical kidney journal2026
Clinical impact of genetic testing in inherited kidney diseases.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inherited kidney diseases (IKDs) and congenital anomalies of the kidney and urinary tract (CAKUT) are a clinically heterogeneous subset of chronic kidney disease and rank among the leading causes of kidney failure (KF), especially in younger patients. Although next-generation sequencing has expanded diagnostic opportunities, data linking genetic findings to clinical outcomes across both adults and children remain limited. Methods: We enrolled 256 patients with suspected IKD (175 adults, 81 children) at a single tertiary center between 2020 and 2023. Genetic testing was performed using targeted panels or exome sequencing, including copy number variant (CNV) and Results: Pathogenic variants were identified in 38.7% of patients. Five genes ( Conclusions: Genetic testing provided clinically relevant diagnoses in nearly 40% of patients with suspected IKD, enabling more accurate prognostication and patient stratification. High yield in cystic disease and pediatric tubular proteinuria, sex-specific survival differences, and CNV analysis highlight the value of integrating genetics into routine nephrology care to guide diagnosis, management, and family counselling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.